Advertisement

Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin

  • Ricardo Avendano
  • Jorge Romero
  • Florentino Lupercio
  • Juan Carlos Diaz
  • Renato Quispe
  • Anjani Golive
  • Andrea Natale
  • Mario J. Garcia
  • Andrew K. Krumerman
  • Luigi Di BiaseEmail author
Article

Abstract

Purpose

Amiodarone is a potent inhibitor of the CYP450:3A4 and inhibitor of the P-glycoprotein, both of which metabolize new oral anticoagulants (NOACs). Patients who are on NOACs and are concomitantly treated with amiodarone may have a higher risk of major bleeding according to recent retrospective trials. Whether this increased risk outweighs the benefits of NOACs compared to warfarin is unknown. We aimed to compare clinical outcomes between NOACs and warfarin in patients with atrial fibrillation (AF) being treated with amiodarone.

Methods

We performed a systematic review of MEDLINE, Cochrane, and Embase for randomized controlled trials that compared NOACs to warfarin for prophylaxis of ischemic stroke/thromboembolic events (TEs) in patients with AF and reported outcomes on TE, major bleeding, and intracranial bleeding (ICB). Risk ratio (RR) and 95% confidence intervals were measured using the Mantel-Haenszel method. Fixed effects model was used, and if heterogeneity (I2) was > 25%, effects were analyzed using a random model.

Results

A total of four studies comparing NOACs to warfarin were included in the analysis. The total number of patients on amiodarone was 6197. Mean follow up was 23 ± 5 months. No statistically significant difference for TE prevention (RR, 0.73; 95% CI 0.50–1.07), major bleeding (RR, 1.02; 95% CI 0.68–1.53), or ICB outcomes (RR, 0.58; 95% CI 0.22–1.51) between patients on NOACs + amiodarone when compared to patients on warfarin + amiodarone.

Conclusion

Among patients with AF taking amiodarone, there is no increased risk of stroke, major bleeding, or ICB with NOACs compared to warfarin.

Keywords

Atrial fibrillation New oral anticoagulants Vitamin K antagonists Amiodarone Clinical outcomes 

Abbreviations

AF

atrial fibrillation

ARISTOTLE

apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial

CYP384

cytochrome p-450 3A4

ENGAGE AF-TIMI 48

effective anticoagulation with factor Xa next generation in atrial fibrillation trial

ICB

intracranial bleeding

INR

internationalized normalized ratio

LSPAF

long-standing persistent atrial fibrillation

NVAF

non-valvular atrial fibrillation

NOAC

new oral anticoagulant

OAC

oral anticoagulation

P-gp

P-glycoprotein

RE-LY

randomized evaluation of long-term anticoagulation therapy trial

ROCKET AF

the rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation

TE

ischemic stroke/thromboembolic events

VKA

vitamin K antagonist

Notes

Author Contributions

RA, J.R, and L.D.B designed the original research idea. R.A and J.R searched studies and extracted data independently. J.R., R.A., F.L., J.C.D., R.Q., A.G., A.N., M.J.G., A.K.K, and L.D.B drafted and approved the present manuscript.

Compliance with ethical standards

Conflict of interest

Dr. Di Biase is a consultant for Biosense Webster, Boston Scientific, and St. Jude Medical, and has received speaker honoraria/travel from Medtronic, St. Jude Medical, Atricure, EPiEP, and Biotronik. The other authors have no pertinent conflicts of interest to report.

Supplementary material

10840_2018_427_MOESM1_ESM.docx (42 kb)
ESM 1 (DOCX 42 kb)

References

  1. 1.
    Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–25.  https://doi.org/10.1161/CIRCULATIONAHA.105.595140.CrossRefGoogle Scholar
  2. 2.
    Di Minno A, Spadarella G, Tufano A, Prisco D, Di Minno G. Ensuring medication adherence with direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKAs). Thromb Res. 2014;133(5):699–704.  https://doi.org/10.1016/j.thromres.2014.01.016.CrossRefGoogle Scholar
  3. 3.
    Contreras Muruaga MDM, Vivancos J, Reig G, Gonzalez A, Cardona P, Ramirez-Moreno JM, et al. Satisfaction, quality of life and perception of patients regarding burdens and benefits of vitamin K antagonists compared with direct oral anticoagulants in patients with nonvalvular atrial fibrillation. J Comp Eff Res. 2017;6(4):303–12.  https://doi.org/10.2217/cer-2016-0078.CrossRefGoogle Scholar
  4. 4.
    Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103(4):307–14.  https://doi.org/10.1136/heartjnl-2016-309832.CrossRefGoogle Scholar
  5. 5.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.  https://doi.org/10.1056/NEJMoa0905561.CrossRefGoogle Scholar
  6. 6.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.  https://doi.org/10.1056/NEJMoa1009638.CrossRefGoogle Scholar
  7. 7.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.  https://doi.org/10.1056/NEJMoa1107039.CrossRefGoogle Scholar
  8. 8.
    Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.  https://doi.org/10.1056/NEJMoa1310907.CrossRefGoogle Scholar
  9. 9.
    Flaker G, Lopes RD, Hylek E, Wojdyla DM, Thomas L, Al-Khatib SM, et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol. 2014;64(15):1541–50.  https://doi.org/10.1016/j.jacc.2014.07.967.CrossRefGoogle Scholar
  10. 10.
    Steffel J, Giugliano RP, Braunwald E, Murphy SA, Atar D, Heidbuchel H, et al. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2015;36(33):2239–45.  https://doi.org/10.1093/eurheartj/ehv201.CrossRefGoogle Scholar
  11. 11.
    Steinberg BA, Hellkamp AS, Lokhnygina Y, Halperin JL, Breithardt G, Passman R, et al. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. Heart Rhythm. 2014;11(6):925–32.  https://doi.org/10.1016/j.hrthm.2014.03.006.CrossRefGoogle Scholar
  12. 12.
    Almog S, Shafran N, Halkin H, Weiss P, Farfel Z, Martinowitz U, et al. Mechanism of warfarin potentiation by amiodarone: dose—and concentration—dependent inhibition of warfarin elimination. Eur J Clin Pharmacol. 1985;28(3):257–61.CrossRefGoogle Scholar
  13. 13.
    Chang SH, Chou IJ, Yeh YH, Chiou MJ, Wen MS, Kuo CT, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA. 2017;318(13):1250–9.  https://doi.org/10.1001/jama.2017.13883.CrossRefGoogle Scholar
  14. 14.
    Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.  https://doi.org/10.1136/bmj.d5928.CrossRefGoogle Scholar
  15. 15.
    Wong KS, Hu DY, Oomman A, Tan RS, Patel MR, Singer DE, et al. Rivaroxaban for stroke prevention in east Asian patients from the ROCKET AF trial. Stroke. 2014;45(6):1739–47.  https://doi.org/10.1161/STROKEAHA.113.002968.CrossRefGoogle Scholar
  16. 16.
    Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1(2):84–91.  https://doi.org/10.1161/CIRCOUTCOMES.108.796185.CrossRefGoogle Scholar
  17. 17.
    Waterman AD, Milligan PE, Bayer L, Banet GA, Gatchel SK, Gage BF. Effect of warfarin nonadherence on control of the international normalized ratio. Am J Health Syst Pharm. 2004;61(12):1258–64.Google Scholar
  18. 18.
    Lupercio F, Romero J, Peltzer B, Maraboto C, Briceno D, Villablanca P, et al. Efficacy and safety outcomes of direct oral anticoagulants and amiodarone in patients with atrial fibrillation. Am J Med. 2018;131(5):573 e1–8.  https://doi.org/10.1016/j.amjmed.2017.11.047.CrossRefGoogle Scholar
  19. 19.
    Coleman CI, Haas S, Turpie AG, Kuhls S, Hess S, Evers T, et al. Impact of switching from a vitamin K antagonist to rivaroxaban on satisfaction with anticoagulation therapy: the XANTUS-ACTS substudy. Clin Cardiol. 2016;39(10):565–9.  https://doi.org/10.1002/clc.22565.CrossRefGoogle Scholar
  20. 20.
    Wang Y, Kong MC, Lee LH, Ng HJ, Ko Y. Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control. Thromb Res. 2014;133(4):550–4.  https://doi.org/10.1016/j.thromres.2014.01.002.CrossRefGoogle Scholar
  21. 21.
    Briceno DF, Villablanca P, Cyrille N, Massera D, Bader E, Manheimer E, et al. Left atrial appendage occlusion device and novel oral anticoagulants versus warfarin for stroke prevention in Nonvalvular atrial fibrillation: systematic review and meta-analysis of randomized controlled trials. Circ Arrhythm Electrophysiol. 2015;8(5):1057–64.  https://doi.org/10.1161/CIRCEP.115.002993.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Montefiore Medical CenterAlbert Einstein College of MedicineBronxUSA
  2. 2.Texas Cardiac Arrhythmia Institute at St. David’s Medical CenterAustinUSA

Personalised recommendations